1
|
Pham TT, Guo Z, Li B, Lapkin AA, Yan N. Synthesis of Pyrrole-2-Carboxylic Acid from Cellulose- and Chitin-Based Feedstocks Discovered by the Automated Route Search. CHEMSUSCHEM 2024; 17:e202300538. [PMID: 37792551 DOI: 10.1002/cssc.202300538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 10/02/2023] [Accepted: 10/04/2023] [Indexed: 10/06/2023]
Abstract
The shift towards sustainable feedstocks for platform chemicals requires new routes to access functional molecules that contain heteroatoms, but there are limited bio-derived feedstocks that lead to heteroatoms in platform chemicals. Combining renewable molecules of different origins could be a solution to optimize the use of atoms from renewable sources. However, the lack of retrosynthetic tools makes it challenging to examine the extensive reaction networks of various platform molecules focusing on multiple bio-based feedstocks. In this study, a protocol was developed to identify potential transformation pathways that allow for the use of feedstocks from different origins. By analyzing existing knowledge on chemical reactions in large databases, several promising synthetic routes were shortlisted, with the reaction of D-glucosamine and pyruvic acid being the most interesting to make pyrrole-2-carboxylic acid (PCA). The optimized synthetic conditions resulted in 50 % yield of PCA, with insights gained from temperature variant NMR studies. The use of substrates obtained from two different bio-feedstock bases, namely cellulose and chitin, allowed for the establishment of a PCA-based chemical space.
Collapse
Affiliation(s)
- Thuy Trang Pham
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, 117585, Singapore City, Singapore
| | - Zhen Guo
- Cambridge Centre for Advanced Research and Education in Singapore (CARES Ltd), 1 CREATE Way, #05-05 Create Tower, 138602, Singapore City, Singapore
- Chemical Data Intelligence (CDI) Pte Ltd, Robinson Road #02-00, 068898, Singapore City, Singapore
| | - Bing Li
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, 117585, Singapore City, Singapore
| | - Alexei A Lapkin
- Cambridge Centre for Advanced Research and Education in Singapore (CARES Ltd), 1 CREATE Way, #05-05 Create Tower, 138602, Singapore City, Singapore
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB3 0AS, UK
| | - Ning Yan
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, 117585, Singapore City, Singapore
| |
Collapse
|
2
|
Caballero‐Camino FJ, Rivilla I, Herraez E, Briz O, Santos‐Laso A, Izquierdo‐Sanchez L, Lee‐Law PY, Rodrigues PM, Munoz‐Garrido P, Jin S, Peixoto E, Richard S, Gradilone SA, Perugorria MJ, Esteller M, Bujanda L, Marin JJ, Banales JM, Cossío FP. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology 2021; 73:186-203. [PMID: 32145077 PMCID: PMC7891670 DOI: 10.1002/hep.31216] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 02/11/2020] [Accepted: 02/23/2020] [Indexed: 12/24/2022]
Abstract
BACKGROUND AND AIMS Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. APPROACH AND RESULTS Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. CONCLUSIONS These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.
Collapse
Affiliation(s)
- Francisco J. Caballero‐Camino
- Department of Organic Chemistry ICenter of Innovation in Advanced Chemistry (ORFEO‐CINQA)University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)Donostia International Physics Center (DIPC)Donostia‐San SebastianSpain,Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain
| | - Ivan Rivilla
- Department of Organic Chemistry ICenter of Innovation in Advanced Chemistry (ORFEO‐CINQA)University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)Donostia International Physics Center (DIPC)Donostia‐San SebastianSpain
| | - Elisa Herraez
- Experimental Hepatology and Drug Targeting (HEVEFARM)Biomedical Research Institute of Salamanca (IBSAL)University of SalamancaSalamancaSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Oscar Briz
- Experimental Hepatology and Drug Targeting (HEVEFARM)Biomedical Research Institute of Salamanca (IBSAL)University of SalamancaSalamancaSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Alvaro Santos‐Laso
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain
| | - Laura Izquierdo‐Sanchez
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Pui Y. Lee‐Law
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain
| | - Pedro M. Rodrigues
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain
| | - Patricia Munoz‐Garrido
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain
| | - Sujeong Jin
- The Hormel InstituteUniversity of MinnesotaAustinMN,Masonic Cancer CenterUniversity of MinnesotaMinneapolisMN
| | - Estanislao Peixoto
- The Hormel InstituteUniversity of MinnesotaAustinMN,Masonic Cancer CenterUniversity of MinnesotaMinneapolisMN
| | - Seth Richard
- The Hormel InstituteUniversity of MinnesotaAustinMN,Masonic Cancer CenterUniversity of MinnesotaMinneapolisMN
| | - Sergio A. Gradilone
- The Hormel InstituteUniversity of MinnesotaAustinMN,Masonic Cancer CenterUniversity of MinnesotaMinneapolisMN
| | - Maria J. Perugorria
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Manel Esteller
- Josep Carreras Leukaemia Research Institute (IJC)BarcelonaSpain,Centro de Investigacion Biomedica en Red Cancer (CIBERONC)MadridSpain,Institucio Catalana de Recerca i Estudis Avançats (ICREA)BarcelonaSpain,Physiological Sciences DepartmentSchool of Medicine and Health SciencesUniversity of Barcelona (UB)BarcelonaSpain
| | - Luis Bujanda
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Jose J.G. Marin
- Experimental Hepatology and Drug Targeting (HEVEFARM)Biomedical Research Institute of Salamanca (IBSAL)University of SalamancaSalamancaSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
| | - Jesus M. Banales
- Department of Liver and Gastrointestinal DiseasesBiodonostia Health Research InstituteDonostia University HospitalUPV/EHUDonostia‐San SebastianSpain,National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain,IKERBASQUEBasque Foundation for ScienceBilbaoSpain
| | - Fernando P. Cossío
- Department of Organic Chemistry ICenter of Innovation in Advanced Chemistry (ORFEO‐CINQA)University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)Donostia International Physics Center (DIPC)Donostia‐San SebastianSpain
| |
Collapse
|
3
|
Synthesis of 2-Benzylidene-3-Pyrrolines and Their Synthetic Transformation. REACTIONS 2020. [DOI: 10.3390/reactions1020005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
A series of benzylidene-3-pyrrolines were prepared from chalcone derivatives, arylacetylene and sulfonamide via a three-step sequence without the isolation of intermediates. Typically, the reaction of 1,3-di-p-tolylprop-2-en-1-one with lithium phenylacetylide was followed by substitution with tosylamide and then silver-catalyzed 5-exo-dig cyclization to give N-tosyl-2-benzylidene-3,5-di-p-tolyl-2,5-dihydro-1H-pyrrole with a 86% yield. Furthermore, transformation to the corresponding substituted 3-pyrrolin-2-one and pyrrole by m-chloroperbenzoic acid (mcpba)-oxidation and acid-catalyzed aromatization, respectively, was investigated.
Collapse
|
4
|
Li M, Sun Y, Xie Y, Yu Y, Huang F, Huang H. Copper-catalyzed carbene insertion and ester migration for the synthesis of polysubstituted pyrroles. Chem Commun (Camb) 2020; 56:11050-11053. [DOI: 10.1039/d0cc04157b] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A mild synthetic protocol to access 2-ester pyrroles through Cu(OTf)2-catalysed carbene insertion/ester migration/cyclization of enaminones and α-diazo compounds is reported.
Collapse
Affiliation(s)
- Mingrui Li
- School of Pharmaceutical Sciences
- Nanjing Tech University
- Nanjing 211816
- P. R. China
| | - Yiming Sun
- School of Pharmaceutical Sciences
- Nanjing Tech University
- Nanjing 211816
- P. R. China
| | - Yuxing Xie
- School of Food Science and Pharmaceutical Engineering
- Nanjing Normal University
- Nanjing 210023
- P. R. China
| | - Yang Yu
- School of Environmental Science and Engineering
- Nanjing Tech University
- Nanjing 211816
- P. R. China
| | - Fei Huang
- School of Pharmaceutical Sciences
- Nanjing Tech University
- Nanjing 211816
- P. R. China
- School of Food Science and Pharmaceutical Engineering
| | - He Huang
- School of Pharmaceutical Sciences
- Nanjing Tech University
- Nanjing 211816
- P. R. China
- School of Food Science and Pharmaceutical Engineering
| |
Collapse
|
5
|
Arrastia I, Arrieta A, Cossío FP. Application of 1,3-Dipolar Reactions between Azomethine Ylides and Alkenes to the Synthesis of Catalysts and Biologically Active Compounds. European J Org Chem 2018; 2018:5889-5904. [PMID: 30555273 PMCID: PMC6283252 DOI: 10.1002/ejoc.201800911] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Indexed: 12/19/2022]
Abstract
The (3+2) cycloaddition between azomethine ylides and alkenes is an efficient, convergent and stereocontrolled method for the synthesis of unnatural pyrrolidine and proline scaffolds. In this review, the application of this reaction to the synthesis of enantiopure organometallic ligands for asymmetric catalysis is presented first. These new EhuPhos ligands can participate in a second generation of 1,3-dipolar reactions that generate an offspring of unnatural proline derivatives that behave as efficient organocatalysts. These densely substituted unnatural l-proline derivatives exhibit distinct features, different to those described for natural l-proline and its derivatives. Finally, several examples of biologically active proline derivatives obtained by means of (3+2) cycloadditions involving azomethine ylides are presented. These applications show the character of privileged structures of these polysubstituted pyrrolidine rings.
Collapse
Affiliation(s)
- Iosune Arrastia
- Donostia International Physics Center (DIPC)Manuel Lardizabal Ibilbidea 420018San Sebastian/DonostiaSpain
| | - Ana Arrieta
- Department of Organic Chemistry I and Centro de Innovación en Química Avanzada (ORFEO‐CINQA)Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU)Manuel Lardizabal Ibilbidea 320018San Sebastian/DonostiaSpain
| | - Fernando P. Cossío
- Donostia International Physics Center (DIPC)Manuel Lardizabal Ibilbidea 420018San Sebastian/DonostiaSpain
- Department of Organic Chemistry I and Centro de Innovación en Química Avanzada (ORFEO‐CINQA)Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU)Manuel Lardizabal Ibilbidea 320018San Sebastian/DonostiaSpain
| |
Collapse
|
6
|
Mishra PK, Verma S, Kumar M, Verma AK. Base-Mediated Direct Transformation of N-Propargylamines into 2,3,5-Trisubstituted 1H-Pyrroles. Org Lett 2018; 20:7182-7185. [DOI: 10.1021/acs.orglett.8b03112] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pawan K. Mishra
- Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Shalini Verma
- Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Manoj Kumar
- Department of Chemistry, University of Delhi, Delhi 110007, India
| | | |
Collapse
|
7
|
Pérez-Salvia M, Aldaba E, Vara Y, Fabre M, Ferrer C, Masdeu C, Zubia A, Sebastian ES, Otaegui D, Llinàs-Arias P, Rosselló-Tortella M, Berdasco M, Moutinho C, Setien F, Villanueva A, González-Barca E, Muncunill J, Navarro JT, Piris MA, Cossio FP, Esteller M. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica 2018; 103:e537-e540. [PMID: 29880608 DOI: 10.3324/haematol.2018.189241] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Montserrat Pérez-Salvia
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | | | | | | | | | - Carme Masdeu
- Department of Organic Chemistry I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), San Sebastián
| | - Aizpea Zubia
- Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián
| | - Eider San Sebastian
- Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián
| | | | - Pere Llinàs-Arias
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | - Margalida Rosselló-Tortella
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | - Maria Berdasco
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | - Catia Moutinho
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | - Fernando Setien
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia
| | - Alberto Villanueva
- Laboratory of Translational Research, Catalan Institute of Oncology (ICO), IDIBELL L'Hospitalet, Barcelona, Catalonia
| | - Eva González-Barca
- Department of Hematology, ICO-Hospital Duran i Reynals, IDIBELL, University of Barcelona, L'Hospitalet, Barcelona, Catalonia
| | - Josep Muncunill
- Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Catalonia
| | - José-Tomás Navarro
- Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Catalonia
| | | | - Fernando P Cossio
- Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián
| | - Manel Esteller
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet, Barcelona, Catalonia .,Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid.,Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), L'Hospitalet, Catalonia.,Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
| |
Collapse
|
8
|
Gao M, Zhao W, Zhao H, Lin Z, Zhang D, Huang H. An efficient and facile access to highly functionalized pyrrole derivatives. Beilstein J Org Chem 2018; 14:884-890. [PMID: 29765469 PMCID: PMC5942380 DOI: 10.3762/bjoc.14.75] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Accepted: 04/03/2018] [Indexed: 01/13/2023] Open
Abstract
A straightforward and one-pot synthesis of pyrrolo[3,4-c]pyrrole-1,3-diones via Ag(I)-catalyzed 1,3-dipolar cycloaddition of azomethine ylides with N-alkyl maleimide, followed by readily complete oxidation with DDQ, has been successfully developed. Further transformation with alkylamine/sodium alkoxide alcohol solution conveniently afforded novel polysubstituted pyrroles in good to excellent yields. This methodology for highly functionalized pyrroles performed well over a broad scope of substrates. It is conceivable that this efficient construction method for privileged pyrrole scaffolds could deliver more active compounds for medicinal chemistry research.
Collapse
Affiliation(s)
- Meng Gao
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| | - Wenting Zhao
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| | - Hongyi Zhao
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| | - Ziyun Lin
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| | - Dongfeng Zhang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| | - Haihong Huang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China
| |
Collapse
|
9
|
Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, de Moura MC, Bradner JE, Gonzalez-Suarez E, Moutinho C, Esteller M. Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. Oncotarget 2017; 8:51621-51629. [PMID: 28881673 PMCID: PMC5584274 DOI: 10.18632/oncotarget.18255] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 05/04/2017] [Indexed: 01/25/2023] Open
Abstract
BET bromodomain inhibitors, which have an antitumoral effect against various solid cancer tumor types, have not been studied in detail in luminal breast cancer, despite the prevalence of this subtype of mammary malignancy. Here we demonstrate that the BET bromodomain inhibitor JQ1 exerts growth-inhibitory activity in human luminal breast cancer cell lines associated with a depletion of the C-MYC oncogene, but does not alter the expression levels of the BRD4 bromodomain protein. Interestingly, expression microarray analyses indicate that, upon JQ1 administration, the antitumoral phenotype also involves downregulation of relevant breast cancer oncogenes such as the Breast Carcinoma-Amplified Sequence 1 (BCAS1) and the PDZ Domain-Containing 1 (PDZK1). We have also applied these in vitro findings in an in vivo model by studying a transgenic mouse model representing the luminal B subtype of breast cancer, the MMTV-PyMT, in which the mouse mammary tumor virus promoter is used to drive the expression of the polyoma virus middle T-antigen to the mammary gland. We have observed that the use of the BET bromodomain inhibitor for the treatment of established breast neoplasms developed in the MMTV-PyMT model shows antitumor potential. Most importantly, if JQ1 is given before the expected time of tumor detection in the MMTV-PyMT mice, it retards the onset of the disease and increases the survival of these animals. Thus, our findings indicate that the use of bromodomain inhibitors is of great potential in the treatment of luminal breast cancer and merits further investigation.
Collapse
Affiliation(s)
- Montserrat Pérez-Salvia
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Laia Simó-Riudalbas
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Pere Llinàs-Arias
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Laura Roa
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Fernando Setien
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Marta Soler
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Manuel Castro de Moura
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - James E Bradner
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Eva Gonzalez-Suarez
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Catia Moutinho
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - Manel Esteller
- Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.,Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
| |
Collapse
|
10
|
Alberro N, Torrent-Sucarrat M, Arrastia I, Arrieta A, Cossío FP. Two-State Reactivity of Histone Demethylases Containing Jumonji-C Active Sites: Different Mechanisms for Different Methylation Degrees. Chemistry 2016; 23:137-148. [DOI: 10.1002/chem.201604219] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Indexed: 01/08/2023]
Affiliation(s)
- Nerea Alberro
- Department of Organic Chemistry I; Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Manuel Lardizabal Ibilbidea 3 20018 San Sebastián/Donostia Spain
| | - Miquel Torrent-Sucarrat
- Department of Organic Chemistry I; Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Manuel Lardizabal Ibilbidea 3 20018 San Sebastián/Donostia Spain
- Donostia International Physics Center (DIPC); Manuel Lardizabal Ibilbidea 4 20018 San Sebastián/Donostia Spain
- Ikerbasque; Basque Foundation for Science; María Díaz de Haro 3, 6 floor 48013 Bilbao Spain
| | - Iosune Arrastia
- Donostia International Physics Center (DIPC); Manuel Lardizabal Ibilbidea 4 20018 San Sebastián/Donostia Spain
| | - Ana Arrieta
- Department of Organic Chemistry I; Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Manuel Lardizabal Ibilbidea 3 20018 San Sebastián/Donostia Spain
| | - Fernando P. Cossío
- Department of Organic Chemistry I; Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU); Centro de Innovación en Química Avanzada (ORFEO-CINQA); Manuel Lardizabal Ibilbidea 3 20018 San Sebastián/Donostia Spain
- Donostia International Physics Center (DIPC); Manuel Lardizabal Ibilbidea 4 20018 San Sebastián/Donostia Spain
| |
Collapse
|
11
|
Conde E, Rivilla I, Larumbe A, Cossío FP. Enantiodivergent Synthesis of Bis-Spiropyrrolidines via Sequential Interrupted and Completed (3 + 2) Cycloadditions. J Org Chem 2015; 80:11755-67. [DOI: 10.1021/acs.joc.5b01418] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Egoitz Conde
- Department of Organic Chemistry
I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Centro de Innovación en Química Avanzada (ORFEO−CINQA), and Donostia International Physics Center (DIPC), P°
Manuel Lardizabal 3, 20018 San Sebastián/Donostia, Spain
| | - Iván Rivilla
- Department of Organic Chemistry
I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Centro de Innovación en Química Avanzada (ORFEO−CINQA), and Donostia International Physics Center (DIPC), P°
Manuel Lardizabal 3, 20018 San Sebastián/Donostia, Spain
| | - Amaia Larumbe
- Department of Organic Chemistry
I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Centro de Innovación en Química Avanzada (ORFEO−CINQA), and Donostia International Physics Center (DIPC), P°
Manuel Lardizabal 3, 20018 San Sebastián/Donostia, Spain
| | - Fernando P. Cossío
- Department of Organic Chemistry
I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Centro de Innovación en Química Avanzada (ORFEO−CINQA), and Donostia International Physics Center (DIPC), P°
Manuel Lardizabal 3, 20018 San Sebastián/Donostia, Spain
| |
Collapse
|
12
|
Costa PRR, Sansano JM, Cossío U, Barcellos JCF, Dias AG, Nájera C, Arrieta A, de Cózar A, Cossío FP. Synthesis of Chromen[4,3-b]pyrrolidines by Intramolecular 1,3-Dipolar Cycloadditions of Azomethine Ylides: An Experimental and Computational Assessment of the Origin of Stereocontrol. European J Org Chem 2015. [DOI: 10.1002/ejoc.201500434] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
13
|
1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. Eur J Med Chem 2015; 89:320-30. [DOI: 10.1016/j.ejmech.2014.10.052] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Revised: 10/14/2014] [Accepted: 10/17/2014] [Indexed: 11/18/2022]
|
14
|
Biodistribution and metabolism of 11C-labeled Kendine 91 in mice and rats. Appl Radiat Isot 2012; 70:2545-51. [DOI: 10.1016/j.apradiso.2012.05.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Accepted: 05/29/2012] [Indexed: 11/24/2022]
|
15
|
Aginagalde M, Gómez-Vallejo V, Vara Y, Cossío FP, Llop J. Synthesis of 11C-labeled Kendine 91, a histone deacetylase inhibitor. Appl Radiat Isot 2012; 70:2552-7. [PMID: 22871301 DOI: 10.1016/j.apradiso.2012.05.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2011] [Revised: 10/04/2011] [Accepted: 05/29/2012] [Indexed: 11/27/2022]
Abstract
In the present paper, the synthesis of (11)C-labeled Kendine 91 (a HDAC inhibitor which has shown in vitro and in vivo activity in HCT 116 and MOLT 4 human cancer cell lines) is described for the first time. The radiosynthesis has been approached by reaction of the non-radioactive precursor 6-((3-(4-hydroxyphenyl)-5-phenyl-1H-pyrrole-2-carboxamide))hexanehydroxamic acid with [(11)C]CH(3)I in basic media. Despite the presence of more than one reactive site in the chemical structure of the precursor, acceptable radiochemical yield (8.2±2.1%, decay corrected to the end of bombardment), specific activity (28.2±9.4 GBq/μmol) and radiochemical purity values (>95%) were obtained in reasonably short preparation times (~40 min). Despite the moderate radiochemical yield, final radioactivity and radioactivity concentration values (1.8±0.3 GBq and 180 MBq/ml, respectively) should be sufficient for putative in vivo studies in animals.
Collapse
Affiliation(s)
- Maialen Aginagalde
- Departamento de Química Orgánica I, Facultad de Química, Universidad del País Vasco--Euskal Herriko Unibertsitatea, Edificio Joxe Mari Korta, Sebastián, Spain
| | | | | | | | | |
Collapse
|
16
|
Huertas D, Soler M, Moreto J, Villanueva A, Martinez A, Vidal A, Charlton M, Moffat D, Patel S, McDermott J, Owen J, Brotherton D, Krige D, Cuthill S, Esteller M. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 2011; 31:1408-18. [PMID: 21804608 PMCID: PMC3312407 DOI: 10.1038/onc.2011.335] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The approval of histone deacetylase inhibitors for treatment of lymphoma subtypes has positioned histone modifications as potential targets for the development of new classes of anticancer drugs. Histones also undergo phosphorylation events, and Haspin is a protein kinase the only known target of which is phosphorylation of histone H3 at Thr3 residue (H3T3ph), which is necessary for mitosis progression. Mitotic kinases can be blocked by small drugs and several clinical trials are underway with these agents. As occurs with Aurora kinase inhibitors, Haspin might be an optimal candidate for the pharmacological development of these compounds. A high-throughput screening for Haspin inhibitors identified the CHR-6494 compound as being one promising such agent. We demonstrate that CHR-6494 reduces H3T3ph levels in a dose-dependent manner and causes a mitotic catastrophe characterized by metaphase misalignment, spindle abnormalities and centrosome amplification. From the cellular standpoint, the identified small-molecule Haspin inhibitor causes arrest in G2/M and subsequently apoptosis. Importantly, ex vivo assays also demonstrate its anti-angiogenetic features; in vivo, it shows antitumor potential in xenografted nude mice without any observed toxicity. Thus, CHR-6494 is a first-in-class Haspin inhibitor with a wide spectrum of anticancer effects that merits further preclinical research as a new member of the family of mitotic kinase inhibitors.
Collapse
Affiliation(s)
- D Huertas
- Bellvitge Biomedical Research Institute, Barcelona, Catalonia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Aginagalde M, Bello T, Masdeu C, Vara Y, Arrieta A, Cossío FP. Formation of γ-Oxoacids and 1H-Pyrrol-2(5H)-ones from α,β-Unsaturated Ketones and Ethyl Nitroacetate. J Org Chem 2010; 75:7435-8. [DOI: 10.1021/jo101388x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Maialen Aginagalde
- Kimika Fakultatea, Kimika Organikoa I Saila, Universidad del País Vasco-Euskal Herriko Uniberstitatea, Manuel de Lardizabal Etorbidea 3, 20018 San Sebastián-Donostia, Spain
| | - Tamara Bello
- Kimika Fakultatea, Kimika Organikoa I Saila, Universidad del País Vasco-Euskal Herriko Uniberstitatea, Manuel de Lardizabal Etorbidea 3, 20018 San Sebastián-Donostia, Spain
| | - Carme Masdeu
- IkerChem, Ltd., Tolosa Etorbidea 72, 20018 San Sebastián-Donostia, Spain
| | - Yosu Vara
- IkerChem, Ltd., Tolosa Etorbidea 72, 20018 San Sebastián-Donostia, Spain
| | - Ana Arrieta
- Kimika Fakultatea, Kimika Organikoa I Saila, Universidad del País Vasco-Euskal Herriko Uniberstitatea, Manuel de Lardizabal Etorbidea 3, 20018 San Sebastián-Donostia, Spain
| | - Fernando P. Cossío
- Kimika Fakultatea, Kimika Organikoa I Saila, Universidad del País Vasco-Euskal Herriko Uniberstitatea, Manuel de Lardizabal Etorbidea 3, 20018 San Sebastián-Donostia, Spain
| |
Collapse
|
18
|
Park H, Kim S, Kim YE, Lim SJ. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem 2010; 5:591-7. [PMID: 20157916 DOI: 10.1002/cmdc.200900500] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The inhibitors of histone deacetylases (HDACs) have drawn a great deal of attention due to their promising potential as small-molecule therapeutics for the treatment of cancer. By means of virtual screening with docking simulations under consideration of the effects of ligand solvation, we were able to identify six novel HDAC inhibitors with IC(50) values ranging from 1 to 100 muM. These newly identified inhibitors are structurally diverse and have various chelating groups for the active site zinc ion, including N-[1,3,4]thiadiazol-2-yl sulfonamide, N-thiazol-2-yl sulfonamide, and hydroxamic acid moieties. The former two groups are included in many drugs in current clinical use and have not yet been reported as HDAC inhibitors. Therefore, they can be considered as new inhibitor scaffolds for the development of anticancer drugs by structure-activity relationship studies to improve the inhibitory activities against HDACs. Interactions with the HDAC1 active site residues responsible for stabilizing these new inhibitors are addressed in detail.
Collapse
Affiliation(s)
- Hwangseo Park
- Department of Bioscience and Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-ku, Seoul 143-747, Korea.
| | | | | | | |
Collapse
|
19
|
V. Ley S, Baumann M, R. Baxendale I, Kirschning A, Wegner J. Synthesis of Highly Substituted Nitropyrrolidines, Nitropyrrolizines and Nitropyrroles via Multicomponent-Multistep Sequences within a Flow Reactor. HETEROCYCLES 2010. [DOI: 10.3987/com-10-s(e)77] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|